Skip to main content

Non-Small Cell Lung Cancer


Conference Coverage
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.
Conference Coverage
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or…
Conference Coverage
Patients with NSCLC who receive pembrolizumab with chemotherapy are more likely to remain on therapy past 90 days than…
True or False: Higher out-of-pocket costs for TKIs among patients with epidermal growth factor receptor- and anaplastic…
Guideline Updates
NCCN released an update to its clinical practice guideline for central nervous system cancers, adding lorlatinib as a…
Back to Top